Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07213791) titled 'A Study of LY4337713 in Participants With FAP-Positive Solid Tumors' on Oct. 7.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Eli Lilly and Company
Condition:
Ovarian Neoplasms
Breast Neoplasms
Pancreatic Intraductal Neoplasms
Colorectal Neoplasms
Esophageal Neoplasms
Stomach Neoplasms
Cholangiocarcinoma
Intervention:
Drug: LY4337713
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: October 2025
Target Sample Size: 241
Countries of Recruitm...